Previous clinical studies have also shown that SPP1 is involved in bone strength and remodelling, suggesting that serum SPP1 positively correlates with lower BMD and that high circulating SPP1 levels could be targeted as a biomarker for early diagnosis of postmenopausal osteoporosis.99 This evidence concerns the gene SPP1 and postmenopausal osteoporosis.